Sherif Abdou: It’s very visible, Ryan. That’s why we’re comfortable calculating the EBITDA. We’re just not prepared to give any guidance on membership revenue or any other items. It will be meaningful growth. It will be new counties. There will be a couple of new payers, there will be some partnerships as well.
Ryan Daniels: Okay. So a little bit of everything. And then a couple of financial questions. The corporate G&A cost, obviously down nicely year-over-year, but still up about $6 million sequentially. I think you mentioned there was an insurance hit of nearly $4 million, which explains a lot of that uptick. I would assume it’s in that line item. But how should we think of that SG&A spend on a go-forward basis for our models? Is this a pretty good quarterly run rate? Or do we need to adjust that?
Atul Kavthekar: No. So for the quarter, I think you hit it correctly. So in the quarter, we actually had about, it was closer to $5 million of a hit. About $3.8 million of it is related to periods outside of the third quarter. So that’s kind of how you can think of a normalized, think of it about $1 million, a little bit over $1 million per quarter. But going forward, I think one of the things that we’ve been stressing here, and you’ve seen some demonstration of it, is a continued prioritization, focus on efficiency. And we’ll just continually get better. I think over time, OpEx will grow as the company grows. But I think it will grow at a much, much slower rate than what you’ve seen in the past. It’s going to be disciplined.
It’s going to be in a way that is more appropriate for a growing company. So I think if you looked at the third quarter, if you shave off about $4 million for sort of out-of-period dollars, I think that gives you a good starting point, but I think that we’ll still expect to see, I’m still expecting to see a little bit of improvement in the fourth quarter. As I said, going into ’24, we’ll give some more specific guidance around that.
Ryan Daniels: No, that’s very helpful though. And then last question, I just want to make sure I have a complete understanding of the nomenclature you’re using. When you talk about persistent lives, can you remind us, is that lives that have been on the platform for more than a year or that were on the platform at the start of like 2022? What defines that because those are some impressive metrics and kind of shows the power of the model over time. So I want to make sure I understand that.
Sherif Abdou: Our definition of persistent is similar to what CMS uses. So the patient that our platform of December of the prior year, as I said on the call, December ’22, the definition of our persistent life in ’23, anybody that was on the platform in December that showed up again in January, that we consider those persistent lives. Some of them have been here only for like a month, some of them have been for 36-plus months, some of them have been for 11 months since the beginning of the year. So that’s the distance traveled.
Ryan Daniels: And do you have an average age of that cohort for patients that are persistent, given that some of them were on in December, but they’ve been on for multiple years? Do you know the age of that cohort? I don’t know if that’s something you calculated.
Sherif Abdou: I’m sure somebody does. So I can get it to you by the end of the day today. As a matter of fact, I’m really going to message our analytics folks. Certainly, somebody does. Yes, I’ll get it to you and I’ll share it with the group.
Operator: Our next question comes from David Larsen with BTIG. Please go ahead.
Jenny Shen: This is Jenny Shen on for Dave Larsen. Congrats on the quarter. I just wanted to know if you could elaborate more on the opportunity that you see with the fully delegated lives. I think you mentioned that you’re ranging around 20% right now. Just the opportunity there and maybe what percent you expect to reach by 2024?
